Non-Melanoma Skin Cancers CPG Mini Module – New Developments in Neoadjuvant Therapy for Non-Melanoma Skin Cancers
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
In this mini module, Emily S. Ruiz, MD, MPH, of Brigham and Women’s Hospital, Harvard University, presents a case study of a patient who received neoadjuvant immunotherapy followed by surgery for in-transit metastatic cutaneous squamous cell carcinoma (cSCC). Dr. Ruiz addresses studies behind this guidance, benefits associated with neoadjuvant immunotherapy, and factors to consider, such as patient selection, surgical window, and adverse events, when determining a course of treatment for patients with aggressive cSCC. The mini-module concludes with a discussion between Isaac Brownell, MD, PhD, of the NIH, and David Miller, MD, PhD, FAAD, of Massachusetts General Hospital, on influential studies on neoadjuvant immunotherapy for Merkle cell carcinoma.
Run Time: 12 Minutes 36 Seconds
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.